Cramer’s lightning round: Zuora is not a buy

23andMe Holding Co: “At $2, I’m willing to buy the lottery ticket. But make no mistake about it, it is a lottery ticket.”

NIO Inc: “I don’t like to buy any of these Chinese stocks. … Let’s move on.”

Mirati Therapeutics Inc: “Understand that you can lose all that you put in. But as a pure spec, I think it’s a good one.”

Zuora Inc: “Zuora’s losing money. … It does not fit our criteria of what you should own.”

Blue Owl Capital Inc: “I’ve got enough problems with major league banks. I do not need to fool around with minor league banks.”

Source

Business

Inside the booming business of wellness third spaces and membership clubs

March 7, 2026

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Business

FDA vaccine head will step down in April after string of controversial decisions

March 6, 2026

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Business

FDA reversals leave investors worrying about the fates of other experimental drugs

March 6, 2026

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]